Quotient Sciences has extended its commercial partnership with Ipsen, focusing on the production of Sohonos (Palovarotene) for fibrodysplasia ossificans progressiva (FOP).
FOP is an ultra-rare condition, impacting fewer than 1,000 people worldwide.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The collaboration involves containment, specialised handling, and sustained supply of this highly potent molecule.
The agreement includes Ipsen’s investment in additional equipment at Quotient Sciences’ facility in Boothwyn, Pennsylvania, US.
This comprises a Pneumatic Closed Transfer System, which maintains blend integrity during safe material transfer, and a Flexible Dispensing Isolator designed to improve operator safety and remove the need for specialised cleaning procedures.
Quotient Sciences now has expanded capabilities for handling highly potent active pharmaceutical ingredients (HPAPI) and products with occupational exposure limits (OELs) at or below 1µg/m³.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe new additions also allow seamless integration with existing equipment, facilitating the production process for complex drug molecules.
The extended partnership aims to guarantee a reliable commercial supply of FOP therapy while expanding capacity to handle multiple highly potent compounds at commercial scale.
This supports the need for flexible solutions in treating rare diseases where patient populations are small and product volumes are limited.
Ipsen selected Quotient Sciences for its established operational capabilities and extensive experience in managing global shipments. The company will be responsible for ensuring the secure and timely delivery of the therapy to international markets.
Quotient Sciences Philadelphia vice-president and general manager Marlene Leuenberger said: “This significant investment in advanced containment and manufacturing technology at our Boothwyn facility underscores Quotient Sciences’ unwavering commitment to supporting patients with ultra-rare diseases.
“By expanding our capabilities in handling highly potent compounds, we are not only ensuring a reliable supply of critical therapies like Sohonos (Palovarotene) for the FOP community, but also reinforcing our promise to deliver flexible, high-quality solutions for our partners with specialised needs, especially for highly potent compounds.”
In September 2025, Quotient Sciences entered a partnership with the UK’s Centre for Process Innovation (CPI) to expedite the creation of ribonucleic acid (RNA)-based treatments.
